menu search

GERN / Geron's Data Allows Development Of Several Catalysts

Geron's Data Allows Development Of Several Catalysts
Primary endpoint of 8-week transfusion independence met in the phase 3 IMerge study; Imetelstat was used as a monotherapy to treat patients with lower-risk myelodysplastic syndrome. Regulatory applications in the U.S. and Europe, of imetelstat for lower-risk myelodysplastic syndrome, are expected in 2023. Read More
Posted: Jan 9 2023, 19:01
Author Name: Seeking Alpha
Views: 110861

GERN News  

Geron Corporation Stock: Another Buying Opportunity

By Seeking Alpha
October 23, 2023

Geron Corporation Stock: Another Buying Opportunity

Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetel more_horizontal

Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs

By Invezz
September 12, 2023

Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs

Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs anal more_horizontal

Why Is Geron (GERN) Stock Up Today?

By InvestorPlace
September 12, 2023

Why Is Geron (GERN) Stock Up Today?

Geron (NASDAQ: GERN ) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares. Goldman Sachs analyst Corinne Jenki more_horizontal

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

By Business Wire
June 7, 2023

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal

Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?

By Zacks Investment Research
June 1, 2023

Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?

Geron Corporation (GERN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GERN's 50 more_horizontal

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMe

By Business Wire
May 11, 2023

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMe

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abs more_horizontal

Why Shares of Geron Are Up 30% This Week

By The Motley Fool
April 20, 2023

Why Shares of Geron Are Up 30% This Week

Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications. more_horizontal

Geron to Present at Upcoming Investor Conferences in April

By Business Wire
April 12, 2023

Geron to Present at Upcoming Investor Conferences in April

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal


Search within

Pages Search Results: